‘Kanarb’ shows off in front of circulatory system experts around the world
A Korean new drug Kanarb in the hypertension market is challenging to the global market beyond the Korean market. The drug is expected to be called the first Korean global drug recognized by both of the Korean and foreign industries. While it is currently recording KRW 40 billion sales annually, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
